Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8422596 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL8237916 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL6156333 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL13104857 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL8237919 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL8235477 | 0.97 | L3MBTL1 (0.39) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| Bromide SCHEMBL3966706 | 0.97 | L3MBTL1 (0.39) | L3MBTL1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL214038 | 0.90 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL939664 | 0.90 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL22389997 | 0.90 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131377-A1 | Combinations of Superoxide Dismutase Mimetics and Nonsteroidal Analgesic/Anti-Inflammatory Drugs | METAPHORE PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7445641-B1 | Biomaterials modified with superoxide dismutase mimics | PHARMACIA CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| WO-2006083508-A2 | COMBINATIONS OF SUPEROXIDE DISMUTASE MIMETICS AND NONSTEROIDAL ANALGESIC/ANTI-INFLAMMATORY DRUGS | METAPHORE PHARMACEUTICALS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | METAPHORE PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171198-A1 | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease | SOD1, MPO, SOD3 | L3MBTL1 3171/4885CXCR4 1255/4885SMN1; SMN2 320/4885 |
| US-20090131377-A1 | Combinations of Superoxide Dismutase Mimetics and Nonsteroidal Analgesic/Anti-Inflammatory Drugs | SOD1, SOD3, CAT | L3MBTL1 2538/4885CXCR4 3758/4885SMN1; SMN2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.